What they mean and why they're important
See where the next discovery will come from
Pledge your next birthday in support of MPN research!
2 October 2014 Japan approves Agrylin for use in Essential Thrombocythemia
3 September 2014 FDA grants orphan drug status to Promedior's PRM-151 for myelofibrosis
5 August 2014 FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
Get news alerts